文献速递前列腺增生与排尿功能障碍

米拉贝隆25mg单药治疗男性OAB合并BOO安全但疗效较低

Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction.
PubMed 文献 · Urology · 2018-04-06

这项前瞻性研究纳入289例接受米拉贝隆25mg单药治疗的男性OAB患者,其中82例(28.4%)合并BOO。治疗后两组满意率相近,但仅无BOO组在IPSS、OABSS及尿急强度感知方面显著改善,且BOO组不良事件发生率更高(18.6% vs 8.2%,P=.026)。

要点

  • 米拉贝隆25mg单药在男性OAB合并BOO患者中安全,但储尿症状改善不如无BOO者。
  • BOO组不良事件发生率18.6%,显著高于无BOO组的8.2%(P=.026)。
  • 两组总体满意率相近:无BOO组61.3%,BOO组57.1%。

核心结论

  • 米拉贝隆25mg单药治疗男性OAB合并BOO安全,但储尿症状改善较少且不良事件率更高。

研究设计与样本

  • 前瞻性纳入年龄≥20岁、接受米拉贝隆25mg每日一次单药治疗的男性OAB患者,共289例,平均年龄71.2岁。
  • 按有无BOO分组:无BOO组207例(71.6%),BOO组82例(28.4%)。
  • 治疗1个月和3个月后采用GRA、IPSS及子评分、OABSS、PPIUS、PPBC和QoL指数评估。

主要发现

  • 两组基线OAB症状相似。
  • 治疗后满意率(GRA评分≥1)无BOO组61.3%,BOO组57.1%,组间相似。
  • 两组QoL指数和PPBC均有改善。
  • 仅无BOO组IPSS及子评分、OABSS和PPIUS显著改善。
  • BOO组不良事件发生率18.6%,显著高于无BOO组的8.2%(P=.026),但多数不良事件为轻度。

临床怎么用

  • 对男性OAB合并BOO患者,米拉贝隆25mg单药治疗安全,但应预期储尿症状改善有限且不良事件风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the therapeutic efficacy and safety of mirabegron monotherapy in male patients with overactive bladder (OAB) with and without bladder outlet obstruction (BOO). MATERIALS AND METHODS: Male patients with OAB aged ≥20 years, with or without BOO, receiving mirabegron 25 mg monotherapy once daily, were prospectively enrolled. The treatment results were assessed using global response assessment, international prostate symptom score and subscores, overactive bladder symptom score, patient perception on intensity of urgency scale, patient perception of bladder condition, and quality of life index at 1 and 3 months after treatment. RESULTS: Of the 289 enrolled patients (mean age, 71.2 years), 207 did not have BOO (71.6%) and 82 had BOO (28.4%). The baseline OAB symptoms were similar between patients with and without BOO. After mirabegron treatment, the satisfactory rate (global response assessment score ≧1) were similar between those without BOO (61.3%) and with BOO (57.1%). The improvement of quality of life index and patient perception of bladder condition was also found in both groups. However, only patients without BOO had significantly improved international prostate symptom score and subscores, overactive bladder symptom score, and patient perception on intensity of urgency scale. Although most adverse events (AEs) were mild, patients with BOO had significantly higher AEs rate (18.6%) than those without BOO (8.2%, P = .026). CONCLUSION: Mirabegron monotherapy in male patients with OAB and BOO was safe. However, the storage symptoms improvement was less in patients with BOO and AEs rate was higher.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Liao CH, Kuo HC. Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. Urology. 2018. PMID: 29630956. doi:10.1016/j.urology.2018.03.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。